{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.4","upperLimit":"6.5","value":"5.15"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"dispersionType":"Full Range","groups":[{"description":"Patients receive bortezomib IV on days 2 and 5 and vorinostat PO QD on days 1-14. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.\n\nBortezomib: Given IV\n\nVorinostat: Given PO","id":"OG000","title":"Arm I (Bortezomib and Vorinostat)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Median Follow-up Survival for All Patients","type":"SECONDARY","unitOfMeasure":"years"}